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Small fibre neuropathy (SFN), a condition dominated by neuropathic pain, is frequently encountered in clinical
practise either as prevalent manifestation of more diffuse neuropathy or distinct nosologic entity. Aetiology of
SFN includes pre-diabetes status and immune-mediated diseases, though it remains frequently unknown. Due
to their physiologic characteristics, small nerve fibres cannot be investigated by routine electrophysiological
tests, making the diagnosis particularly difficult.Quantitative sensory testing (QST) to assess the psychophysi-
cal thresholds for cold and warm sensations and skin biopsy with quantification of somatic intraepidermal nerve
fibres (IENF) have been used to determine the damage to small nerve fibres. Nevertheless, the diagnostic
criteria for SFNhave not been defined yet and a‘gold standard’ forclinicalpractise andresearch is not available.
We screened 486 patients referred to our institutions and collected 124 patients with sensory neuropathy.
Among them, we identified 67 patients with pure SFN using a new diagnostic ‘gold standard’ , based on the
presence of at least two abnormal results at clinical, QSTand skin biopsy examination. The diagnosis of SFN
was achieved by abnormal clinical and skin biopsy findings in 43.3% of patients, abnormal skin biopsy and QST
findings in 37.3% of patients, abnormal clinical and QST findings in 11.9% of patients, whereas 7.5% patients had
abnormal results at all the examinations. Skin biopsy showed a diagnostic efficiency of 88.4%, clinical examina-
tion of 54.6% and QST of 46.9%. Receiver operating characteristic curve analysis confirmed the significantly
higher performance of skin biopsy comparing with QST. However, we found a significant inverse correlation
between IENF density and both cold and warm thresholds at the leg. Clinical examination revealed pinprick
and thermal hypoesthesia in about 50% patients, and signs of peripheral vascular autonomic dysfunction in
about 70% of patients. Spontaneous pain dominated the clinical picture in most SFN patients. Neuropathic
pain intensity was more severe in patients with SFN than in patients with large or mixed fibre neuropathy,
but there was no significant correlation with IENF density.The aetiology of SFN was initially unknown in 41.8%
of patients and at 2-year follow-up a potentialcause couldbe determinedin 25% of them.Over the same period,
13% of SFN patients showed the involvement of large nerve fibres, whereas in 45.6% of them the clinical picture
did not change. Spontaneous remission of neuropathic pain occurredin10.9% of SFN patients, while it worsened
in 30.4% of them.
Keywords: neuropathy; pain; skin biopsy; quantitative sensory testing; neurophysiology
Abbreviations: CMAP=compound motor action potential; CDT=cold detection threshold; CPT=cold pain thresholds;
HPT=heat pain thresholds; IENF=intraepidermal nerve fibres; IGT=impaired glucose tolerance; LEPs=laser evoked
potentials; LFN=large fibre neuropathy; MFN=mixed (large and small) fibre neuropathy; MGUS=monoclonal gammopathy
of undetermined significance; NCS=nerve conduction study; NRS=numerical rating scale; PT=perceptive thresholds;
QST=quantitative sensory testing; ROC=receiver operating characteristic; SFN=small fibre neuropathy;
SNAP=sensory nerve action potential; VAS=visual analogue scale; WDT=warm detection threshold
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In the last decade, after the availability of new tools for
investigating unmyelinated C and thinly myelinated Ad
fibres, small fibre neuropathy (SFN) has been recognized as
a distinct nosologic entity. Although small fibres encompass
thermal and nociceptive sensation as well as autonomic
functions, SFN commonly refers to somatic neuropathy
alone and the overlap with the term ‘painful neuropathy’ is
accepted. When autonomic dysfunctions prevail, the defi-
nition of ‘autonomic neuropathy’ is used. Small fibres are
invisible to routine nerve conduction studies and their
damage most frequently causes a neuropathic pain syn-
drome, making the diagnosis of SFN often particularly
difficult. In fact, spontaneous and stimulus-evoked positive
sensory symptoms frequently dominate the clinical picture
and can hide the signs of small fibre loss, namely thermal
and pinprick hypoesthesia. Moreover, conditions other than
nerve fibre damage may mimic SFN, including venous
insufficiency, spinal stenosis, myelopathy and psychoso-
matic disturbances.
In the literature, the definition of SFN reflected the
methods used by the different authors to assess nerve fibre
dysfunction, including clinical and neurophysiological
findings, changes in thermal and pain thresholds using
psychophysical tests and neuropathological examination
using nerve biopsy or skin biopsy with intraepidermal
nerve fibre (IENF) quantification. Non-conventional neu-
rophysiological techniques, such as cutaneous silent period
examination (Osio et al., 2004), and new devices such as
laser evoked potentials (LEPs) (Truini et al., 2004) and
contact heat evoked potentials (Atherton et al., 2007) have
been also used to assess small fibre dysfunction in patients
with peripheral neuropathy, with the aim to demonstrate
specific findings for diagnosing SFN. Overall, these studies
have contributed to increase the awareness on SFN among
neurologists and others specialists, such as diabetologists,
but did not lead to a definition of the syndrome. Thus, the
absence of a diagnostic ‘gold standard’ for SFN remains a
limitation in clinical practise and research.
Skin biopsy has been included in the diagnostic work-up
of patients with suspected SFN after the availability of
antibodies against the protein-gene-product 9.5, a predom-
inantly neuronal form of ubiquitin carboxyl-terminal
hydrolase transported with the slow component of the
axonal transport (Wilkinson et al., 1989), which allowed
demonstrating the extensive innervation of the epidermis.
IENF are somatic unmyelinated C-fibres and express the
capsaicin receptor, indicating that they are nociceptors
(Lauria et al., 2006). Skin biopsy can reliably demonstrate
the loss of IENF in SFN, thus confirming the diagnosis
when clinical and neurophysiologic examinations are not
informative (Lauria et al., 2005; Gibbons et al., 2006).
Moreover, this technique has been used to show that small
fibres degenerate early in the course of neuropathies
associated with diabetes and HIV infection, and that their
morphological changes may predict the progression to a
more diffuse neuropathy (Lauria et al., 2003; Gibbons et al.,
2006; Herrmann et al., 2006). Although the availability of
skin biopsy has been a major advance for diagnosing SFN,
the correlation between IENF density and neuropathic pain
remains unclear. In fact, a complete denervation of the
epidermis can be seen in patients both with persisting
neuropathic pain and genetic insensitivity to pain (Nolano
et al., 2000; Lauria et al., 2006), thus raising the question
whether the loss of IENF itself is causally related to pain or
it is only an indicator of neuropathy. Data from the
literature suggest that a more severe loss of IENF increases
the risk to develop neuropathic pain, whereas IENF
regeneration can be associated with a decrease in pain
intensity (Sommer and Lauria, 2007).
We conducted a retrospective analysis of a large cohort
of patients with sensory neuropathy and identified homo-
geneous groups of patients according the type of nerve fibre
involvement. The first aim of our study was to compare
specificity and sensitivity of clinical examination, quantita-
tive sensory testing (QST) and skin biopsy in order to
propose a reliable definition of SFN using a multimodal
diagnostic approach. The second aim was to analyse the
correlation between the different features of neuropathic
pain in patients with SFN and the density of IENF to
understand whether skin biopsy may predict the clinical
picture and the progression of the disease.
Patients and Methods
We screened the clinical files of 486 patients referred to our
institutions for suspected sensory neuropathy from January 1,
2004 to May 31, 2007. Patients eligible for the present study did
have to fulfil the following criteria: (i) symptoms suggesting
sensory neuropathy; (ii) availability of clinical and neuroalgologic
examinations, including intensity and characteristics of sponta-
neous and stimulus-evoked pain; (iii) availability of sensory and
motor nerve conduction study (NCS) in at least two sensory and
two motor nerves at both upper and lower limbs; (iv) availability
of skin biopsy with quantification of IENF density at the proximal
thigh and the distal leg; (v) availability of warm and cooling
thresholds at the foot assessed by QST. A subgroup of patients
underwent also LEPs and laser Doppler flowmetry.
Clinical and neuroalgologic examinations
We aimed at identifying the clinical signs of neuropathy and the
quality and intensity of pain. Presence and distribution (e.g. length
or non-length dependent) of sensory loss and pain, gait impairment
and dysautonomic symptoms (e.g. pupil abnormalities, impotence,
impaired bladder function, constipation or diarrhoea, early satiety
andgastricfullness,abnormal sweating,flushing,skindecolouration,
xerostomia and xerophthalmia, orthostatic hypotension) were
recorded. Patients were asked to report whether they experienced
thermal allodynia (e.g. taking the shower) and/or pain in the feet
while walking, wearing certain shoes or touching the sheets. In all
patients, we assessed the diagnosis of restless leg syndrome using the
questionnaire revised by the International Restless Legs Syndrome
Study Group (Allen et al., 2003).
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order to identify negative sensory signs (sensory loss) and positive
sensory signs (evoked and spontaneous pain, paraesthesias, restless
leg syndrome). The neurological examination was performed using
cotton gauze (light touch and dynamic mechanic allodynia test),
disposable safety needle (hypoalgesia, pinprick hyperalgesia, after-
sensation test), glass vials filled with cold and hot water (thermal
sensation, allodynia test, aftersensation test) and 128Hz Rydel-
Seiffer tuning fork (vibration at the first metatarsal joints, ankles,
knees, first metacarpal joints, elbows). Sense of movement and
position of toes and hand fingers were evaluated. Deep tendon
reflexes were graded as normal, decreased (if present with
reinforcement) or absent. Muscle strength was graded using the
Medical Research Council (MRC) score. Positive Romberg’s sign
and gait abnormalities were recorded.
Patients were diagnosed with mononeuropathy, multiplex
mononeuropathy, polyneuropathy and sensory neuronopathy.
Polyneuropathy was distinguished in SFN, large fibre neuropathy
(LFN) and mixed (large and small) fibre neuropathy (MFN).
Intensity of spontaneous pain, allodynia [static mechanical
(pressure), dynamic mechanical (brush), heat or cold (thermal)]
and hyperalgesia were graded using the 10cm visual analogue scale
(VAS). We used the following descriptors for pain: throbbing,
lancinating, unpredictable, lightning-like, sharp, shooting, aching,
burning, scalding, pruritic (Galer and Jensen, 1997).
In all patients, the aetiology of neuropathy was recorded and
further exams were performed when appropriate. In particular,
patients were screened for diabetes and impaired glucose tolerance
(IGT), vitamin B12 and folate deficiency, thyroid diseases,
hyperlipidemia, malignancies, hepatitis C, HIV infection and use
of neurotoxic drugs. When appropriate, serum and urine protein
immunofixation, autoantibodies, antibodies against gangliosides
and sulphatide, onconeuronal antigens and neoplastic markers
were analysed.
Neurophysiological tests
Patients underwent motor and sensory NCS using surface
recording electrodes with standard placement. Normal lower
values for ulnar and median sensory nerve action potential
(SNAP) amplitude and conduction velocity (antidromic technique
from fifth to second finger) were 420mV and 450m/s, whereas
those for sural SNAP amplitude and conduction velocity were
46mV and 442m/s. Compound motor action potential (CMAP)
amplitude and conduction velocity of peroneal, tibial, ulnar and
median nerves were examined. A difference of at least 50% in
SNAP and CMAP amplitude was required to define a significant
asymmetry between sides. When appropriate, F-wave examination
of the same nerves was carried out by delivering 20 random
stimuli and minimal latency was corrected by height.
Electromyography was performed with standard concentric
needle in at least one proximal and one distal muscle of the
extremities. A minimum of at least three areas with fibrillation
potentials and/or positive sharp waves was required to identify a
muscle as having spontaneous activity at rest. Motor unit potential
changes and maximal recruitment pattern were evaluated with a
semiquantitative recording.
In all patients who had already undergone NCS in other
hospitals, we analysed the traces in order to verify the reliability of
the examination and referred to the report signed by the
neurophysiologist. When the traces were not available or the
quality of the recording did not appear reliable or the test had
been performed more than 3 months before, we repeated the
examination.
Assessment of thermal thresholds
Warm, cold, heat pain and cold pain thresholds were assessed
using the Medoc
TM device (Medoc
TM Thermal Sensory Analyser,
TSA-2001, Israel). Thermal thresholds were quantified using a
3030mm probe at the dorsum of the foot and at the same sites
where skin biopsies where taken (see subsequently). Warm and
cooling detection thresholds (CDT, WDT) were evaluated with the
method of limits, with ramp stimuli of 1C/s from 32C. Values
were compared with the database of age- and sex-matched
normative values. Results above the 95th percentile were
considered abnormal. Abnormal sensation (errata sensation,
paradoxical thermal sensation and thermal allodynia or hyper-
algesia) and presence of aftersensation were recorded during the
exams in an ad hoc table. Verbal pain rating [using the 11-point
numerical rating scale (NRS)] was used to assess the intensity of
cold and heat pain thresholds (CPT and HPT). We calculated
warm and cold sensibility index to determine the pain sensitivity
range in which thermal sensations were perceived (Jensen et al.,
1991). Cold sensibility index was defined as: (cold pain detection
threshold  cold threshold)/(cold pain detection threshold 
reference temperature). Warm sensibility index was defined as:
(warm pain detection threshold  warm threshold)/(warm pain
detection threshold  reference temperature).
Skin biopsy
Our two skin biopsy laboratories have been following a yearly
quality control programme for all the steps of the procedure that
has guaranteed the inter-laboratory agreement on the quantifica-
tion of IENF density, based on periodic exchange of slides for
blind counting. In all patients and control healthy subjects
included in the present study, skin biopsies were obtained from
the proximal region of the thigh (20cm below the anterior iliac
spine) and the distal region of the leg (10cm above the lateral
malleolus, within the sural nerve territory). Biopsies were taken
after local anaesthesia using a 3mm disposable punch under sterile
technique. Three sections randomly chosen from each biopsy were
immunoassayed with polyclonal anti-protein-gene-product 9.5
antibodies (Biogenesis Ltd, Poole, UK; 1:1000) using the free-
floating protocol for bright field immunohistochemistry previously
described (Lauria et al., 2004). The linear density of IENF (IENF/
mm) was calculated following the rules reported by the guidelines
of the European Federation of the Neurological Societies (Lauria
et al., 2005).
Laser Doppler flowmetry
Skin blood flow was measured using the laser Doppler flowmetry
(PeriFlux
TM, Perimed PF4, Stockholm, Sweden), which measures
skin blood flow in perfusion units (PU), representing the product
of velocity and concentration of the moving blood cells within
the volume measured. The 780nm wave length light generated
by the laser is directed to the skin using an optic-fibre probe and
reflects from the moving blood cells undergoing a shift in
frequency (Doppler effect). The thermostatic laser Doppler
probes, which include recording and heating elements, heat the
underlying skin area while blood perfusion is recorded. All the
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and 27C, with the subject lying awake in a clinostatic position.
The probes were placed at the dorsum of the foot, at the same
areas in which skin biopsies were performed (see above), and at
the tip of the toe and of second finger of the hand. The probe
temperature was 32C during the baseline measurement. We
measured the following parameters: skin temperature; basal
cutaneous blood flow recorded continuously throughout the
stimulation protocol; vasoconstriction reflexes induced by deep
breathing and postural variation (veno-arteriolar reflex); vasodi-
latation induced by local heating (from 32Ct o4 4 C for 6min).
Vasoconstriction reflexes induced by deep breathing examine
sympathetic adrenergic function, whereas veno-arteriolar reflex
and vasodilatation induced by local heating investigate skin axonal
reflexes carried by somatic C-fibres.
LEPs
We used a neodymium Laser (Nd: YAP) stimulator (79–119
mJ/mm
2, 5ms, 4mm, Ad input) able to elicit pinprick sensation
activated by Ad-fibres and warm sensation carried by C-fibres
(38.2–63.7 mJ/mm
2, 10ms, 10mm, C input). The stimulator with
optic-fibre guidance was placed on a skin area of about 6cm
2 at
the dorsal aspect of right hand, distal leg and dorsal foot. To
determine the laser perceptive thresholds (PT), we delivered series
of stimuli at different intensity and recorded the average pain
rating for each site. We defined the PT as the lower intensity at
which the subjects perceived at least 50% of the stimuli (Truini
et al., 2005). Before starting LEPs recording, we delivered noxious
laser pulses on the sites to be stimulated with the aim of
familiarizing the patients and adjusting the energy of stimulation.
This allowed obtaining a moderately painful pinprick sensation,
with target pain rating 4 on the 11-point NRS (0=no sensation,
3=pain threshold, 10=worst possible pain). Stimuli were
delivered randomly, with intervals of 10–20s between each
consecutive pair of stimuli to avoid central habituation. The
N2-P2 complex was recorded using surface disc electrodes from
vertex (Cz) referenced to the earlobes (A1-A2). The early N1
component was recorded from T3 and T4 referenced to Fz. The
electro-oculographic recording monitored eye movements and
blinks. We averaged two series of 10–12 artefact-free trials for each
site of stimulation and measured latency and amplitude of the
main N2-P2 components and N1. Data were compared with the
values obtained in 18 healthy subjects matched for age and sex.
We analysed differences of laser PT using the Mann–Whitney test
and differences in latency and amplitude of LEPS using the
unpaired t-test.
Criteria to diagnose SFN
Patients were diagnosed with SFN when at least two of
the following examinations were abnormal: (i) clinical signs of
small fibre impairment (pinprick and thermal sensory loss and/or
allodynia and/or hyperalgesia), which distribution was consistent
with peripheral neuropathy (length or non-length dependent
neuropathy); (ii) abnormal warm and/or cooling threshold at
the foot assessed by QST; (iii) reduced IENF density at the
distal leg.
SFN was ruled out in the presence of: (i) any sign of large fibre
impairment (light touch and/or vibratory and/or proprioceptive
sensory loss and/or absent deep tendon reflexes); (ii) any sign of
motor fibre impairment (muscle waste and/or weakness); (iii) any
abnormality on sensorimotor NCS.
Statistical analysis
Statistical analysis was performed using the MannWhitney test
or unpaired t-test, when appropriate. Values 50.05 were
considered significant. The diagnostic yield of skin biopsy and
QST was estimated by the area under the receiver operating
characteristic (ROC) curve. The diagnostic yield of clinical
examination, QST and skin biopsy for diagnosing SFN was
calculated comparing each test versus the gold standard as defined
following the criteria above mentioned (e.g. abnormal findings in
at least two of three evaluations).
Results
Diagnosis and aetiology
A total of 150 patients (77 women and 73 men) met the
entry criteria for the study. Sensory neuropathy was
diagnosed in 124 patients (61 women and 63 men) with
age ranging from 22 to 84 years [mean 6014 SD]. Basing
on clinical, neurophysiological, QST and skin biopsy
findings, we classified the patients as affected by SFN
(54%), LFN (17.7%), MFN (16.9%), sensory neuronopathy
(4%), demyelinating sensory neuropathy (1.6%), sensory
mononeuropathy (3.2%) and multiplex mononeuropathy
(2.4%). We could define the aetiology of neuropathy in 66
patients (53.2%), whereas it remained unknown in 58
patients (47%). Neuropathy was associated with diabetes in
23 patients (18.5%), IGT in eight patients (6%), mono-
clonal gammopathy of undetermined significance (MGUS)
in eight patients (6%), Sjo ¨gren’s syndrome in five patients
(4%), hepatitis C virus in four patients (3.2%), anti-myelin
associated glycoprotein antibodies in two patients (1.6%),
sensory Guillain-Barre ´ syndrome in two patients (1.6%),
other rheumatological diseases (undifferentiated connective
tissue disorders, rheumatoid arthritis, psoriasic arthropathy)
in six patients (4.8%), anti-neoplastic drugs in two patients
(1.6%), hypothyroidism in three patients (2.4%), nerve
entrapment in two patient (1.6%), celiac disease in one
patient (0.8%). Figure 1 details the diagnostic categories
based on the type of nerve fibre involvement and the
aetiology of SFN.
In 26 patients with sensory disturbances in the feet, the
diagnosis of neuropathy was ruled out after clinical and
neurophysiological examination, QST and skin biopsy. In
seven of them with progressive gait impairment and
chronic back pain, electromyography showed neurogenic
changes of motor unit potentials suggesting lumbosacral
radiculopathy and spine magnetic resonance imaging
revealed lumbar spine stenosis. In six patients complaining
of spontaneous pain with atypical distribution (e.g. pain
throughout the body, transient pain in different regions of
the body), a defined psychiatric illness (e.g. psychotic
depression) was diagnosed. Finally, three patients were
diagnosed with venous insufficiency in the legs.
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Neuropathic pain dominated the clinical picture in 110
patients, whereas 14 patients complained of non-painful
paraesthesias. Overall, 31 patients (28.2%) had spontaneous
pain and nine patients (8.2%) had evoked pain alone,
whereas the remaining 70 patients (63.6%) complained of
both spontaneous and evoked pain. Evoked pain alone
was characterized by static light touch allodynia in four
Fig. 1 Flow diagram showing the various categories of sensory neuropathies diagnosed after clinical examination, nerve conduction
studies,QSTand skin biopsy.The aetiology of SFN at first observation and at 2-year follow-up is detailed.
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associated with warm allodynia in one of them. Considering
the quality of pain, patients were divided into the following
three larger groups: burning pain (69.2%), sharp pain
(30.7%) and ‘sunburn-like’ pain (24.4%). Paroxysmal pain
dominated the clinical picture in 4.5% of patients and it was
associated with ongoing burning pain in 10.9% of patients.
Painwas described aspruritic in 4.4% of patients, deep aching
in 2.2% of patients and cold in 1.1% of patients (Table 1).
Five patients (4%) with MFN fulfilled the criteria for restless
leg syndrome. In the SFN group, 40 patients (59.7%) had
both spontaneous and evoked pain, 26 patients (38.8%)
had only spontaneous pain and only one patient had evoked
pain alone (dynamic mechanic and warm allodynia).
The intensity of neuropathic pain at VAS was 44i n9 1
patients (82.7%) and 54 in 19 patients (17.3%). When
comparing the different subtypes of neuropathy, we found
that pain was much more frequent in patients with SFN
than in the other groups and its intensity was44 at VAS in
most cases (Fig. 2). NCS results were normal in SFN
patients, whereas revealed an axonal sensory neuropathy in
patients with LFN and MFN (Table 2). In all patients with
LFN and MFN, clinical examination showed signs of large
fibre impairment, whereas evoked pain was present in
77.6% of patients. Clinical examination revealed pinprick
and thermal hypoesthesia in 52.2% and evoked pain in
59.7% of patients with SFN (Table 3).
Table 2 Sensory and motor NCS results in different
types of painful sensory neuropathy
SFN (n=67) L FN( n=23) M FN( n=20)
Median nerve
SNAP (mV) 22.926 . 5 55 . 5 4
SCV (m/s) 55.135 2  25 0 1.5
CMAP (mV) 12.2 3.4 10 2.3 91.8
MCV (m/s) 52.8 25 2 . 2  2.3 50.2 2
DL (ms) 3.5 13 . 6 13 . 9 1.4
F-wave (ms) 26.532 6 . 5 22 6 3
Ulnar nerve
SNAP (mV) 35.071 2 . 0  41 4 . 0 3
SCV (m/s) 54.245 0 . 1 34 9 . 1 2
CMAP (mV) 6.8 25 . 4 26 2
MCV (m/s) 54.2 5.3 52.244 9 . 2 3
F-wave l (ms) 27.53.2 27.2  22 6 . 2  2
Sural nerve
SNAP (mV) 18.23.5 2.3 3.7 5.0  8.2
SCV (m/s) 42.52.4 41.61.2 42 1.8
Peroneal nerve
CMAP (mV) 5.0 24 . 5 1.8 4.2 0.9
MCV(m/s) 49.2  24 8 . 2 34 6 . 2  2
DL (ms) 3.9 13 . 9 1.4 3.8 1.2
F-wave l (ms) 48.334 9 24 8 3
Tibial nerve
CMAP(mV) 5.8 14 . 6 35 . 9 1
MCV(m/s) 54.2 44 8 . 4 24 9 . 2  2
DL (ms) 4.8 24 24 . 8 1
F-wave l (ms) 50.25.3 50  4.6 503.7
Value are expressed as meanSD. MCV=motor conduction
velocity; DL=distal latency; SCV=sensory conduction velocity.
Fig. 2 Correlation between intensity of neuropathic pain and type
of neuropathy in124 patients.‘Others’ include mononeuropathies
and sensory neuronopathies.‘No neuropathy’ include patients in
whom the diagnosis of neuropathy was ruled out.
Table 1 Features and intensity of spontaneous pain in
different types of painful sensory neuropathy
SFN LFN MFN
No. pts
(%)
VAS No. pts
(%)
VAS No. pts
(%)
VAS
Burning pain 36 (53.7) 6.5 3 (13) 4.5 12 (60) 6.5
Sharp pain 11 (16.4) 7 .2 9 (39) 5.2 3 (15) 4.5
Sunburn pain 8 (11.9) 8.0 0 ^ 2 (10) 5.5
Paroxysmal
pain
a
3 (4.5) 9 2 (8.7) 7 .5 1 (5) 9.4
Pruritic pain 4 (5.9) 6.8 0 ^ 0 ^
Deep aching
pain
3 (4.5) 5.2 5 (21.7) 4.8 1 (5) 6.4
Cold pain 2 (3) 6.5 1 (4.3) 4.0 1 (5) 5.3
aPain intensity measured withVAS during the attacks.
Table 3 Clinical findings and features of evoked pain
in 67 patients with SFN
No. of patients (%) NRS
Pinprick hypoesthesia 25 (37.7) ^
Warm hypoesthesia 12 (17 .9) ^
Cold hypoesthesia 5 (7 .4) ^
Static light touch allodynia 4 (5.9) 7
Dynamic mechanic allodynia 1 (1.5) 5
Warm allodynia 14 (20.9) 8
Cold allodynia 18 (26.8) 7
Hyperalgesia 13 (19.4) 5
Aftersensation 8 (11.9) 4
The intensity of evoked pain was measured by the11-point NRS.
Percentage refers to the dominating clinical finding, since all
patients showed more than one single type of sensory defect
and pain.
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The cut-off values of IENF density were calculated using the
ROC curve analysis comparing patients with 47 healthy
subjects. Values of 12.8IENF/mm at proximal thigh and
7.63IENF/mm at distal leg were associated with specificity
of 57.5 and 90% and sensibility of 95.5 and 82.8%, respec-
tively (Fig. 3). Spearman’s correlation between laboratories
for IENF density quantification was 0.87. IENF density at the
distal leg was abnormal in 59 patients (88%) with SFN and in
17 patients (81%) with MFN, whereas it was normal in all
patients with LFN (Table 4). IENF density at the distal leg was
normal in six patients with psychiatric illness (9.922.5), in
seven patients with lumbar stenosis (9.32.3) and in three
patients with venous insufficiency (12.50.14).
QST findings
CDT, WDT, CPT and HPT were measured in all patients
with neuropathy and in 24 healthy controls (Fig. 4).
Sensory threshold for at least one thermal modality was
abnormal in 38 patients (57.5%) with SFN, in 10 patients
(47.6%) with MFN and in 12 patients (54.4%) with LFN,
comparing with healthy subjects. In all patients, both WDT
and CDT were altered at foot and distal leg, whereas WDT
was abnormal also at the proximal thigh in 5.5% of SFN
and MFN patients and CPT in 1.4% of patients.
In the group of SFN, 31 patients (46.2%) had abnormal
CDT (17 at foot, 13 at distal leg, none at proximal thigh),
and seven patients (10.4%) had errata perception para-
esthesias or warm sensation (all at distal leg). Twelve
patients (14.9%) had cold allodynia (12 at foot, two at
distal leg and two at proximal thigh) with lower cold
sensibility index (0.169) than patients without cold
allodynia (20.21) and healthy subjects (30.8). Twenty-
three patients (34%) had abnormal WDT (23 at foot, 16 at
distal leg and five at proximal thigh). Twenty-two patients
(32.8%) had heat hyperalgesia with mean intensity of
7.31.5 at the 11-point NRS (22 at foot, two at distal
leg, three at proximal thigh), and only one had heat
allodynia (T540C) at foot, with lower warm sensibility
Fig. 3 ROC analysis of IENF density at the proximal thigh (A)a n dt h ed i s t a ll e g( B) in1 10 patients with painful sensory neuropathy
and 47 healthy controls. At the proximal thigh, the cut-off value was12.8 IENF/mm (SE=0.035, area under the curve=0.825 and 95%
CI=0.756^0.882). At the distal leg, the cut-off value was 7 .63 IENF/mm (SE=0.026, area under the curve=0.906 and
95% CI = 0.849^ 0.947).
1918 Brain (2008),131,1912^1925 G. Devigili et al.index (0.95) than SFN patients without warm allodynia
(6.26) and healthy subjects (15.8) (Fig. 5).
Six patients (30%) with MFN had abnormal CDT (six
at foot, four at distal leg, none at proximal thigh) and
three patients (15%) had errata perception paraesthesias or
warm sensation (all at distal leg). Four patients (5.9%) had
cold allodynia (three at foot, one at distal leg, one at
proximal thigh). Eight patients (40%) had abnormal WDT
(eight at foot, three at distal leg, one at proximal thigh).
Fig. 4 QSTat dorsal foot, distal leg and proximal thigh in healthy controls (CTRL) and patients with SFN, MFN and LFN. Box plots
represent the median value with 25th and 75th percentiles.
Table 4 Mean density (S D )o fI E N Fa tp r o x i m a lt h i g h( P t h )
and distal leg (Dl) in healthy controls and patients with SFN,
MFN and LFN
No. Pth Dl
Controls 47 21.74.9 9.83.6
SFN 67 12.96.9 4.43.6
MFN 21 12.8 7.9 4.3 3.1
LFN 22 21.5 6.3 11.02.6
The diagnostic criteria for SFN Brain (2008),131, 1912^1925 1919One patient (5%) had heat allodynia (at foot), while seven
(35%) had heat hyperalgesia with NRS mean 7.41.5
(seven at foot, three at distal leg, one at proximal thigh).
Five patients (21.7%) with LFN had abnormal CDT
(three at foot, three at distal leg, none at proximal thigh),
and one patient had errata perception paraesthesias or
warm sensation (at distal leg). No patient had cold
allodynia. Eight patients (34.8%) had abnormal WDT (six
at foot, two at distal leg, none at proximal thigh). Three
patients (13%) had heat hyperalgesia with NRS mean
6.661.5 (at foot and distal leg).
Diagnostic yield of skin biopsy, QSTand
clinical findings in SFN
The diagnosis of SFN was based on abnormal clinical and
skin biopsy findings in 43.3% of patients, on abnormal
clinical and QST findings in 11.9% of patients and on
abnormal skin biopsy and QST findings in 37.3% of
patients. Only 7.5% of patients showed abnormal results at
all the three examinations. We calculated the diagnostic
efficiency (weighed summation of specificity and sensibility)
of clinical examination, QST and skin biopsy against the
proposed gold standard for the diagnosis of SFN. Skin
biopsy showed a diagnostic efficiency of 88.4%, clinical
examination of 54.6% and QST of 46.9% (Table 5). ROC
analysis confirmed the significantly higher performance of
skin biopsy comparing with QST (Fig. 6).
Correlation between skin biopsy, intensity of
pain and QST in patients with SFN
We found a trend toward an inverse correlation between
intensity of pain and IENF density at the proximal thigh,
but not at the distal leg (Fig. 7). IENF density at distal leg
was significantly lower (P=0.003) in patients with pure
spontaneous pain (n=31) than in patients with pure
evoked pain (n=9). We found a significant (P50.0001)
inverse correlation between IENF density and all the
thermal thresholds at the dorsum of the foot and at the
distal leg (Fig. 8), whereas at the proximal thigh there was a
significant correlation only with warm and HPT
(P50.005), but not with cold threshold.
Autonomic signs and functional tests in SFN
Clinical signs of autonomic dysfunction were present in 32
patients (47.8%) with SFN: 18 patients had hypo-anidrosis,
12 patients had flushing or other vasomotor dysfunctions
and two patients had Adie’s pupils with post-ganglionic
hypersensibility to 0.1% pilocarpine test. Laser Doppler
flowmetry was abnormal in 51 patients (76.1%), whereas
16 patients (32.9%) showed abnormal temperature and basal
cutaneous blood flow with inverted hand-foot gradient.
Vasoconstriction reflexes to deep breathing at the foot were
Fig. 6 ROC analysis in 67 patients with SFN comparing the
diagnostic yield of skin biopsy with quantification of IENF and
QSTat the distal leg. Area under the ROC was 0.904 for IENF
density (SE=0.027; 95% CI=0.841^0.947) and was 0.576 for QST
(SE=0.049; 95% CI=0.488^0.660). Difference between areas
was 0.328 (SE = 0.053; 95% CI = 0.225^ 0.431; P50.001).
Fig. 5 Distribution of abnormal QST findings in 67 patients with
SFN.ES=errata sensation; CS=cold sensation; WS=warm sensa-
tion; CP=cold pain; HP=heat pain.
Table 5 Diagnostic efficiency of clinical examination,
QSTand skin biopsy at the distal leg against the
diagnostic ‘gold standard’ for small fibre neuropathy
Clinical
examination (%)
QST
(%)
Skin
biopsy (%)
Sensibility 62.6 56.7 88
Specificity 46 36.5 88.8
Positive predictive
value
55.3 48.7 89.4
Negative predictive
value
53.7 44.2 87 .5
1920 Brain (2008),131,1912^1925 G. Devigili et al.abnormal in 11 patients (16.4%) and veno-arteriolar reflex
was abnormal in 18 patients (26.8%). Vasodilatation
response to local heating was reduced in 42 patients
(38.8%): in 26 patients at the foot, in 20 patients at the
distal leg and one patient at the proximal thigh.
LEPs in SFN
We analysed 10 patients with SFN and 18 healthy subjects.
PT was determined for Ad and C-nociceptors at the dorsal
aspect of right hand, distal leg and dorsal foot. Late-Ad
LEPs induced a pinprick sensation at the irradiated sites
both in healthy subjects and SFN patients. The PT did not
differ between controls and patients at the dorsal aspect of
the hand, whereas it was significantly higher in patients
at the lower limb (P50.0007 at dorsal foot; P50.0009 at
distal leg; Mann–Whitney test). Ultralate-C LEPs evoked a
warm sensation at the irradiated sites in 16 healthy subjects
and in six patients with SFN. Two healthy subjects and four
SFN patients perceived burning pinprick and were excluded
from the analysis.
Reproducible late-Ad LEPs were recorded in all healthy
subjects and in most SFN patients after stimulation of
hand, foot and distal leg. Conversely, reproducible ultralate-
C LEPs could be recorded in most healthy subjects and SFN
patients at the distal leg, but only in few controls and
patients at the foot. The N2-P2 complex could not be
recorded after Ad-fibre stimulation at the dorsal foot in two
patients and the distal leg in one patient. The N2-P2
complex was delayed in latency in one patient after
stimulation at both foot and distal leg. In the other
patients, latency and peak-to-peak amplitude of N2-P2
complex did not differ from healthy subjects (Table 6).
Natural course of SFN
We could follow-up 46 of 67 patients (68.5%) with SFN
over a mean period of 22.37.4 (SD) months (range
6–32), including the 28 patients formerly diagnosed with
idiopathic SFN. Patients with idiopathic SFN underwent
follow-up screening to assess a potential aetiology, which
was found in seven of them (25%): four patients developed
diabetes, two patients had IGT and one patients was
diagnosed with Sjo ¨gren syndrome.
In six patients (13%), clinical and NCS follow-up
demonstrated the involvement of large nerve fibres thus
changing the diagnosis in MFN. Four of them had a known
aetiology (diabetes in two patients and MGUS in two
patients), whereas two patients with initially idiopathic SFN
developed diabetes (Fig. 1). Spontaneous remission of
neuropathic pain occurred in five patients (10.9%).
Conversely, 14 patients (30.4%) experienced a worsening
of pain intensity. In 21 patients (45.6%), clinical and
neurophysiological evaluations did not differ from the first
observation.
Fig. 8 Correlation analysis of IENF density (IENF/mm), (CDT; A)
and (WDT; B) at the distal leg in patients with SFN. Data did
not show a normal distribution. Non-parametric MannWhitney
U-test demonstrated the significant correlation between
IENF/mm and both CDT (P50.0001) and WDT (P50.0001) at
the distal leg.
Fig. 7 Correlation between intensity of pain measured by theVAS
and the linear innervation density of the epidermis (IENF/mm) at
proximal thigh (Pth) and distal leg (Dl) in 67 patients with SFN. No
significant correlation was found.
The diagnostic criteria for SFN Brain (2008),131,1912^1925 1921Discussion
The need of reliable criteria for the diagnosis of SFN comes
both from clinical practise and research. Small fibres, which
can be early affected in systemic diseases like diabetes, are
invisible to neurophysiological investigations and their
impairment can cause a chronic neuropathic pain syn-
drome predominantly involving the feet. Degeneration of
small nerve fibres can predict the progression to a more
diffuse neuropathy (Lauria et al., 2003; Gibbons et al., 2006;
Herrmann et al., 2006), making the early diagnosis of SFN
important for the correct treatment of patients. Recent
studies have also suggested that subclinical involvement of
most distal large sensory fibres can occur in SFN
(Herrmann et al., 2004; Sharma et al., 2007).
SFN encompasses several aetiologies, including diabetes
and pre-diabetes conditions, hypothyroidism, hyperlipide-
mia, statin and anti-retroviral therapy (McManis et al.,
1994; Moore et al., 2000; Smith et al., 2001; Lo et al., 2003;
Sumner et al., 2003; Orstavik et al., 2006), immune-
mediated and connective tissue disorders (Hoitsma et al.,
2002; Brannagan et al., 2005; Gondim et al., 2005; Mori
et al., 2005; Goransson et al., 2006; Gorson et al., 2008),
infective diseases (Kaida et al., 1997; Zhou et al., 2007),
paraneoplastic syndromes (Oki et al., 2007) and genetic
diseases (Sto ¨gbauer et al., 1999; Dutsch et al., 2002; Nolano
et al., 2006). In several patients, the aetiology may remain
unknown (Hoitsma et al., 2004; De Sousa et al., 2006).
Therefore, patients complaining of symptoms suggesting
SFN must be diagnosed for at least three main reasons.
First, the definition of the diagnosis can lead to a focused
screening on its aetiology. Second, early disease modifying
or symptomatic treatments can be started. Third, the
awareness of the disease can increase patients’ compliance,
which is particularly important in the treatment of
neuropathic pain.
In the last decade, the interest in the field of SFN has
increased much, new diagnostic tools have been developed
and several reviews have been published (Santiago et al., 1999;
Al-Shekhlee et al., 2002; Lacomis, 2002; Said, 2003; Hoitsma
et al., 2004; Lauria, 2005; Fink and Oaklander, 2006;
Goodman, 2007; Horowitz, 2007). Nevertheless, relatively
few studies have investigated into details homogeneous
groups of patients with SFN and compared the yield of the
different diagnostic tools available (Holland et al., 1998;
Schuller et al., 2000; Dutsch et al., 2002; Brannagan et al.,
2005; Zambelis et al., 2005; Goransson et al., 2006; Orstavik
et al., 2006; Sorensen et al., 2006a, b; Gorson et al., 2008; Walk
etal.,2007).Inparticular,therehasbeenlittleemphasisonthe
value of clinical examination. The general view of SFN is that
of a quite stereotypical neuropathic syndrome, though little is
known about the different features of pain, the prevalence of
somatic and autonomic abnormalities, and its natural course
(Hoitsma et al., 2004).
Our study provided a comprehensive analysis of a large
group of patients with painful neuropathy, among whom
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1922 Brain (2008),131,1912^1925 G. Devigili et al.67 patients with pure SFN were identified. SFN was defined
using narrow criteria, based on clinical examination, QST
and skin biopsy rather than on the description of symptoms
and signs alone. Skin biopsy showed the highest sensibility,
specificity and positive and negative predictive values,
confirming the result of several previous studies (Lauria
et al., 2005; Gibbons et al., 2006; Loseth et al., 2006; Walk
et al., 2007). Our findings confirmed the concordance
between skin biopsy and sensory examination previously
observed in patients with SFN (Herrmann et al., 2004; Walk
et al., 2007). Therefore, this technique, introduced in
clinical practise only about one decade ago, demonstrated
to provide reliable diagnostic information when there is
little or no clinical evidence of neuropathy, such as it may
happen in patients complaining of burning feet, and to
distinguish conditions mimicking a neuropathy. Reduced
epidermal innervation density has been used as mandatory
criteria for diagnosing SFN (Holland et al., 1998).
Nevertheless, our study showed that skin biopsy results
can be normal in about 10% of patients in whom SFN is
diagnosed by clinical and QST examination. This finding
emphasizes that a multimodal approach to SFN using the gold
standard, we have proposed can better describe the diagnostic
spectrum possibly encountered in clinical practise.
Interestingly, clinical examination with evaluation of
negative (hypoesthesia) and positive (evoked pain) signs
correlated with the diagnosis of SFN in about half of
patients, showing a higher diagnostic efficiency than QST.
This finding strengthens the assumption that a thorough
clinical evaluation should drive the diagnostic work-up in
patients with peripheral neuropathy (England et al., 2005).
SFN is commonly considered a condition in which most
patients have a normal clinical examination. Conversely, we
have demonstrated that it happens only in about one-third
of patients that is the group in which the diagnosis was
achieved by skin biopsy and QST alone. Distribution and
course of sensory symptoms and clinical signs can help in
differentiating length-dependent sensory axonopathies from
non-length-dependent sensory neuronopathies (Sghirlanzoni
et al., 2005). However, in patients with non-length-dependent
pattern of sensory disturbances limited to small fibre
impairment, the presence of abnormal findings at clinical
and QST examination alone may not rule out a myelopathy,
which should be taken into account in the differential
diagnosis of SFN.
Assessment of thermal thresholds using psychophysical
techniques has been widely used to investigate the function
of small nerve fibres. However, this approach proved to be
more useful in population studies than in single patients
(Shy et al., 2003; Hansson et al., 2007). The expected
correlation between cold and/or warm threshold, conveyed
by Ad and C-fibres, respectively, and IENF density was
found in some (Pan et al., 2003; Pittenger et al., 2004; Shun
et al., 2004; Sorensen et al., 2006a; Quattrini et al., 2007),
but not all (Holland et al., 1997; Facer et al., 1998; Periquet
et al., 1999) the previous studies. However, no study has
previously analysed skin biopsy and QST within the same
area. We observed a significant inverse correlation between
IENF density and thermal thresholds at the distal leg,
namely at the site commonly used to diagnose SFN with
skin biopsy. Thus, the lack of concordance reported in
some studies might be ascribed also to the different site
where QST was performed, besides the relatively less
homogeneity of the study population comparing with our
study. Nevertheless, assessment of small fibre damage using
QST showed a lower diagnostic efficiency than both clinical
examination and skin biopsy. In particular, the low value of
specificity, which is an important parameter when diagnosis
or treatment may be harmful to patients, reflects the known
difficult of psychophysical tests to correctly identify whether
in individual subjects results are normal or abnormal
(Hansson et al., 2007).
One further question still unaddressed is whether the
innervation density of the epidermis influences features and
intensity of neuropathic pain. Indeed, two opposite
conditions—acquired painful neuropathy and congenital
insensitivity to pain—are characterized by loss of IENF
(Nolano et al., 2000; Lauria et al., 2006). Data from the
literature appears somewhat discordant. Skin denervation
causes pinprick and pain sensory loss that recover after
nerve regeneration (Lauria et al., 1998; Simone et al., 1998;
Nodera et al., 2003; Smith et al., 2006). Reduced density of
IENF at the distal leg, which is typically found in patients
with painful neuropathy, correlated with pain intensity in
some (Polydefkis et al., 2002; Zhou et al., 2007) but not all
(Herrmann et al., 2006; Sorensen et al., 2006b) the studies.
We found that patients with SFN complained of more
severe pain than those with involvement of large sensory
fibres. The features of neuropathic pain reflected the
predominant impairment of Ad and C-fibre, since sponta-
neous pain, thermal allodynia and hyperalgesia were most
frequently reported (Baron, 2006). Moreover, IENF density
at the distal leg was significantly lower in patients with pure
spontaneous pain than in patients with pure evoked pain.
Nevertheless, we did not find any significant correlation
between IENF density at the lower limb and intensity of pain.
Therefore, our understanding remains that a more severe loss
of IENF may increase the risk to develop neuropathic pain,
whereas IENF regeneration may be associated with a decrease
in pain intensity (Sommer and Lauria, 2007).
Autonomic dysfunction is a common finding in patients
with SFN, but it is likely underestimated in clinical practise.
A previous study (Novak et al., 2001) reported a higher
frequency of vascular deregulation in the lower limbs than
cardiovascular autonomic impairment. Similarly, we found
that SFN is associated with clinical signs of dysautonomia,
which were most commonly limited to sweating and
peripheral vascular impairment. Functional examination
of small fibres by laser Doppler flowmetry confirmed the
impairment of reflex mechanisms ensuring vasoconstriction
and vasodilatation of peripheral blood vessels in most
patients with SFN.
The diagnostic criteria for SFN Brain (2008),131,1912^1925 1923Among non-conventional neurophysiological tests, LEPs
have been proposed to investigate SFN (Truini et al., 2004).
We did not find significant differences in latency and
amplitude of late and ultralate LEPs, reflecting Ad and C
fibre activation, respectively. Therefore, we could not
explore any possible correlations with IENF density, clinical
findings or QST results, which have been previously
investigated only in single case reports (Perretti et al.,
2003; Chiang et al., 2005). However, ultralate LEPs, which
reflect the activation of the same class of fibres innervating
the epidermis, cannot be recorded in all healthy subjects.
Since damage to C-fibres implies the disappearance or the
decrease in amplitude of the evoked potentials, there is
need of comparative studies involving larger population of
controls and patients.
Finally, we could examine the clinical course of SFN in a
large cohort of patients over a follow-up period of 2 years.
A potential aetiology could be determined in 25% of
patients with a former diagnosis of idiopathic SFN. In most
of them, diabetes or IGT was discovered. This finding
emphasizes the importance of glucose tolerance test in the
diagnostic work-up of patients with painful neuropathy
(Sumner et al., 2003). Follow-up investigations revealed the
progression to MFN only in a small number of patients.
In most patients with SFN, the clinical picture did not
change, but one-third of them experienced a worsening of
neuropathic pain intensity.
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